Drugs / QLS2313
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07294300 | Jan 2026 → Feb 2028 expected | refractory hematologic cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS2313 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07294300 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT07294300 ↗ |